clinical trial · NCT05373901
Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma
BeiGene·phase1·completed·n = 8
High-risk NeuroblastomaDinutuximab Beta13-cis-Retinoic Acid
brief summary
This was an open-label, multi-center, single-arm, Phase 1 study. The purpose of this study was for evaluating the safety and pharmacokinetics of dinutuximab beta as maintenance therapy in Chinese participants with high-risk neuroblastoma
started
Jun 7, 2022
primary completion
Jun 29, 2023
completion
Jun 29, 2023
last updated
Oct 4, 2024
official title
An Open-Label, Multi-Center, Single-Arm, Phase 1 Study Evaluating the Safety and Pharmacokinetics of Dinutuximab Beta as Maintenance Therapy in Chinese Patients With High-Risk Neuroblastoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol